ArticleDiabetologia2026
Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL
Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03269058. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Dapagliflozin on Lipoprotein Kinetics in Patients With Type 2 Diabetes
Open the trial in the graphWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aims/hypothesisSGLT2 inhibitors reduce atherosclerosis, but their effect on lipid metabolism remains unclear. Animal studies have suggested that SGLT2 inhibitors may decrease LDL catabolism by reducing the hepatic expression of LDL receptors. However, the effect of SGLT2 inhibitors on LDL metabolism, and more widely on all ApoB-containing lipoproteins, remain unknown in humans. This prompted us to study the effect of the SGLT2 inhibitor dapagliflozin on the metabolism of ApoB100-containing lipoproteins in individuals with type 2 diabetes.
methodsWe performed a parallel double-blinded in vivo kinetic study using stable isotopes (tri-deuterated [
resultsCompared with placebo-treated individuals (n=7), those who received dapagliflozin (n=17) showed a significant reduction of body weight (p<0.001) and HbA CONCLUSIONS/
interpretationDapagliflozin does not impair the catabolism of LDL in individuals with type 2 diabetes. It reduces direct catabolism of VLDL
trial registrationClinicalTrials.gov NCT03269058
fundingThe study was funded via grants and support from AstraZeneca, the French National Research Agency (ANR) under the programme 'Investissements d'Avenir', the University of Burgundy-Franche-Comté, the National Institute of Health and Medical Research (Inserm), the Region Burgundy - Franche Comté, and the Fonds Européens de Développement Régional.
Indexed as
Identifiers
42467086What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.